Expanding mechanistic insights into the pathogenesis of idiopathic [CD4.sup.+] T cell lymphocytopenia
Idiopathic [CD4.sup.+] T cell lymphocytopenia (ICL) is a heterogeneous syndrome presenting with persistent [CD4.sup.+] T cell lymphopenia of unknown origin, and opportunistic infections in some patients. The underlying pathogenesis and appropriate management remain understudied. In this issue of the...
Gespeichert in:
Veröffentlicht in: | The Journal of clinical investigation 2020-10, Vol.130 (10), p.5105 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 10 |
container_start_page | 5105 |
container_title | The Journal of clinical investigation |
container_volume | 130 |
creator | Campos, Jose S Henrickson, Sarah E Abraham, Roshini S |
description | Idiopathic [CD4.sup.+] T cell lymphocytopenia (ICL) is a heterogeneous syndrome presenting with persistent [CD4.sup.+] T cell lymphopenia of unknown origin, and opportunistic infections in some patients. The underlying pathogenesis and appropriate management remain understudied. In this issue of the JCI, Perez-Diez and Wong et al. assessed the prevalence of autoantibodies from the sera of 51 adult ICL patients (out of a cohort of 72). Some patients showed high levels of IgG and IgM autoantibodies against numerous autoantigens, and some autoantibodies were specific for lymphocytes. The researchers implicate these autoantibodies as a possible pathogenic mechanism responsible for the reduction in circulating [CD4.sup.+] T cells. This study goes beyond defining a mechanism in a complex, poorly defined disease; it also brings a renewed focus on ICL that will likely result in improved diagnostic evaluation and treatment. |
doi_str_mv | 10.1172/JCI141717 |
format | Article |
fullrecord | <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A637941270</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A637941270</galeid><sourcerecordid>A637941270</sourcerecordid><originalsourceid>FETCH-LOGICAL-g2040-12ed408fcd70a1c5b709b1d5cf8edfdab857e21c48aac2c32bfddc6d5d9048363</originalsourceid><addsrcrecordid>eNqNz1FLwzAQB_AgCs7pg98gIAgirUmaLumj1KmTwUCnLyIjTdI20iZlyWD79nbowwZ7kHu448_vDg6AS4xijBm5e8knmGKG2REY4DTlEScJPwYDhAiOMpbwU3Dm_TdCmNKUDoAerzthlbEVbLWshTU-GAmN9aaqg--H4GCoNexEqF2lrfbGQ1dCo4zbZj3-zB9o7FddfPsF51DqpoHNpu1qJzfBddoacQ5OStF4ffHXh-D9cTzPn6Pp7GmS30-jiiCKIky0ooiXUjEksEwLhrICq1SWXKtSiYKnTBMsKRdCEpmQolRKjlSqMkR5MkqG4Or3biUavTC2dGEpZGu8XNyPEpZRTBjqVXRAbX9bisZZXZo-3vPxAd-X0q2RBxdu9hZ6E_Q6VGLl_WLy9vp_O_vYt9c7ttaiCbV3zSoYZ_0u_AFujZ_T</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Expanding mechanistic insights into the pathogenesis of idiopathic [CD4.sup.+] T cell lymphocytopenia</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Campos, Jose S ; Henrickson, Sarah E ; Abraham, Roshini S</creator><creatorcontrib>Campos, Jose S ; Henrickson, Sarah E ; Abraham, Roshini S</creatorcontrib><description>Idiopathic [CD4.sup.+] T cell lymphocytopenia (ICL) is a heterogeneous syndrome presenting with persistent [CD4.sup.+] T cell lymphopenia of unknown origin, and opportunistic infections in some patients. The underlying pathogenesis and appropriate management remain understudied. In this issue of the JCI, Perez-Diez and Wong et al. assessed the prevalence of autoantibodies from the sera of 51 adult ICL patients (out of a cohort of 72). Some patients showed high levels of IgG and IgM autoantibodies against numerous autoantigens, and some autoantibodies were specific for lymphocytes. The researchers implicate these autoantibodies as a possible pathogenic mechanism responsible for the reduction in circulating [CD4.sup.+] T cells. This study goes beyond defining a mechanism in a complex, poorly defined disease; it also brings a renewed focus on ICL that will likely result in improved diagnostic evaluation and treatment.</description><identifier>ISSN: 0021-9738</identifier><identifier>EISSN: 1558-8238</identifier><identifier>DOI: 10.1172/JCI141717</identifier><language>eng</language><publisher>American Society for Clinical Investigation</publisher><subject>Autoantibodies ; Autoantigens ; Autoimmunity ; B cells ; Belimumab ; Health aspects ; Immunoglobulin G ; Infection ; Lymphocytopenia ; T cells</subject><ispartof>The Journal of clinical investigation, 2020-10, Vol.130 (10), p.5105</ispartof><rights>COPYRIGHT 2020 American Society for Clinical Investigation</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Campos, Jose S</creatorcontrib><creatorcontrib>Henrickson, Sarah E</creatorcontrib><creatorcontrib>Abraham, Roshini S</creatorcontrib><title>Expanding mechanistic insights into the pathogenesis of idiopathic [CD4.sup.+] T cell lymphocytopenia</title><title>The Journal of clinical investigation</title><description>Idiopathic [CD4.sup.+] T cell lymphocytopenia (ICL) is a heterogeneous syndrome presenting with persistent [CD4.sup.+] T cell lymphopenia of unknown origin, and opportunistic infections in some patients. The underlying pathogenesis and appropriate management remain understudied. In this issue of the JCI, Perez-Diez and Wong et al. assessed the prevalence of autoantibodies from the sera of 51 adult ICL patients (out of a cohort of 72). Some patients showed high levels of IgG and IgM autoantibodies against numerous autoantigens, and some autoantibodies were specific for lymphocytes. The researchers implicate these autoantibodies as a possible pathogenic mechanism responsible for the reduction in circulating [CD4.sup.+] T cells. This study goes beyond defining a mechanism in a complex, poorly defined disease; it also brings a renewed focus on ICL that will likely result in improved diagnostic evaluation and treatment.</description><subject>Autoantibodies</subject><subject>Autoantigens</subject><subject>Autoimmunity</subject><subject>B cells</subject><subject>Belimumab</subject><subject>Health aspects</subject><subject>Immunoglobulin G</subject><subject>Infection</subject><subject>Lymphocytopenia</subject><subject>T cells</subject><issn>0021-9738</issn><issn>1558-8238</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNqNz1FLwzAQB_AgCs7pg98gIAgirUmaLumj1KmTwUCnLyIjTdI20iZlyWD79nbowwZ7kHu448_vDg6AS4xijBm5e8knmGKG2REY4DTlEScJPwYDhAiOMpbwU3Dm_TdCmNKUDoAerzthlbEVbLWshTU-GAmN9aaqg--H4GCoNexEqF2lrfbGQ1dCo4zbZj3-zB9o7FddfPsF51DqpoHNpu1qJzfBddoacQ5OStF4ffHXh-D9cTzPn6Pp7GmS30-jiiCKIky0ooiXUjEksEwLhrICq1SWXKtSiYKnTBMsKRdCEpmQolRKjlSqMkR5MkqG4Or3biUavTC2dGEpZGu8XNyPEpZRTBjqVXRAbX9bisZZXZo-3vPxAd-X0q2RBxdu9hZ6E_Q6VGLl_WLy9vp_O_vYt9c7ttaiCbV3zSoYZ_0u_AFujZ_T</recordid><startdate>20201001</startdate><enddate>20201001</enddate><creator>Campos, Jose S</creator><creator>Henrickson, Sarah E</creator><creator>Abraham, Roshini S</creator><general>American Society for Clinical Investigation</general><scope>IOV</scope><scope>ISR</scope></search><sort><creationdate>20201001</creationdate><title>Expanding mechanistic insights into the pathogenesis of idiopathic [CD4.sup.+] T cell lymphocytopenia</title><author>Campos, Jose S ; Henrickson, Sarah E ; Abraham, Roshini S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g2040-12ed408fcd70a1c5b709b1d5cf8edfdab857e21c48aac2c32bfddc6d5d9048363</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Autoantibodies</topic><topic>Autoantigens</topic><topic>Autoimmunity</topic><topic>B cells</topic><topic>Belimumab</topic><topic>Health aspects</topic><topic>Immunoglobulin G</topic><topic>Infection</topic><topic>Lymphocytopenia</topic><topic>T cells</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Campos, Jose S</creatorcontrib><creatorcontrib>Henrickson, Sarah E</creatorcontrib><creatorcontrib>Abraham, Roshini S</creatorcontrib><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><jtitle>The Journal of clinical investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Campos, Jose S</au><au>Henrickson, Sarah E</au><au>Abraham, Roshini S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expanding mechanistic insights into the pathogenesis of idiopathic [CD4.sup.+] T cell lymphocytopenia</atitle><jtitle>The Journal of clinical investigation</jtitle><date>2020-10-01</date><risdate>2020</risdate><volume>130</volume><issue>10</issue><spage>5105</spage><pages>5105-</pages><issn>0021-9738</issn><eissn>1558-8238</eissn><abstract>Idiopathic [CD4.sup.+] T cell lymphocytopenia (ICL) is a heterogeneous syndrome presenting with persistent [CD4.sup.+] T cell lymphopenia of unknown origin, and opportunistic infections in some patients. The underlying pathogenesis and appropriate management remain understudied. In this issue of the JCI, Perez-Diez and Wong et al. assessed the prevalence of autoantibodies from the sera of 51 adult ICL patients (out of a cohort of 72). Some patients showed high levels of IgG and IgM autoantibodies against numerous autoantigens, and some autoantibodies were specific for lymphocytes. The researchers implicate these autoantibodies as a possible pathogenic mechanism responsible for the reduction in circulating [CD4.sup.+] T cells. This study goes beyond defining a mechanism in a complex, poorly defined disease; it also brings a renewed focus on ICL that will likely result in improved diagnostic evaluation and treatment.</abstract><pub>American Society for Clinical Investigation</pub><doi>10.1172/JCI141717</doi><tpages>4</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0021-9738 |
ispartof | The Journal of clinical investigation, 2020-10, Vol.130 (10), p.5105 |
issn | 0021-9738 1558-8238 |
language | eng |
recordid | cdi_gale_infotracmisc_A637941270 |
source | EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
subjects | Autoantibodies Autoantigens Autoimmunity B cells Belimumab Health aspects Immunoglobulin G Infection Lymphocytopenia T cells |
title | Expanding mechanistic insights into the pathogenesis of idiopathic [CD4.sup.+] T cell lymphocytopenia |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T03%3A25%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expanding%20mechanistic%20insights%20into%20the%20pathogenesis%20of%20idiopathic%20%5BCD4.sup.+%5D%20T%20cell%20lymphocytopenia&rft.jtitle=The%20Journal%20of%20clinical%20investigation&rft.au=Campos,%20Jose%20S&rft.date=2020-10-01&rft.volume=130&rft.issue=10&rft.spage=5105&rft.pages=5105-&rft.issn=0021-9738&rft.eissn=1558-8238&rft_id=info:doi/10.1172/JCI141717&rft_dat=%3Cgale%3EA637941270%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A637941270&rfr_iscdi=true |